In this exclusive interview with Livewire, NDF Research Senior Analyst discusses ImpediMed (ASX: IPD), a company that has been one of the poster children of the Life Sciences sector on ASX over the last two years.
Livewire is Australia’s source of financial intelligence - visit www.livewiremarkets.com.
If you want to know why ASX-listed Life Sciences companies are worth taking a look at in 2016, consider ImpediMed (ASX: IPD), now a A$540m company. When I had lunch with CEO Rick Carreon and CFO CFO Morten Vigeland in mid-2013 their company was capitalised at a mere $20m or so. ImpediMed was arguably the world leader in medical devices using bioimpedance spectroscopy to noninvasively monitor the fluid status of patients. The company had gained FDA approval for L-Dex, a new generation diagnostic for lymphoedema, which can hit up to one in five women after breast cancer surgery. But before Rick Carreon, previously a successful Medtronic executive, ImpediMed hadn't figured out how to get paid for L-Dex. Rick and Morten shared with me their plans for fixing that problem and, sure enough, by September 2014, L-Dex had the needed reimbursement, not just for breast cancer but for all cancer-related lymphoedema. Every time our Life Sciences sector attracts a Rick Carreon to help it out - and he has been a generous supporter - we move to a higher level.
Note - the usual disclaimers apply - click here.